RxDoctor Payments Data

John Jiu, MD

Otolaryngology/Facial Plastic Surgery · Jonesboro, ARNPI 1871568808

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $3,083 of the $3,619 with a category attached, or 85.2%. It is spread thinly across 21 manufacturers, the largest accounting for just 18.8% — the pattern of someone who eats at a lot of different presentations.

$3,619in general payments, 2019–2025

Across 133 payments — averaging $27.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron Healthcare Solutions, Inc.$681
  • GSK$623
  • Inspire Medical Systems, Inc.$595
  • Intersect ENT, Inc.$372
  • Sanofi$253
  • Phathom Pharmaceuticals, Inc.$210
  • plus $885 from 15 others

What the payments were for

  • Travel & lodging$2858%
  • Food & beverage$3,08385%
  • Education$2517%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few otolaryngology/facial plastic surgery providers in Arkansasto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$125,026
Medicare patients
513
Services billed
3,020

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NucalaMepolizumab13$47,955
Ipratropium Bromide62$1,922
Azelastine Hcl24$727
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav23$405
Propylthiouracil12$384
Fluticasone Propionate34$351
Ofloxacin11$205
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen18$116
Nortriptyline Hcl12$106
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim18$94
Prednisone17$88

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKNucala$623$47,95513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few otolaryngology/facial plastic surgery providers in Arkansason file to place this against a meaningful peer group, so we don't.

Other otolaryngology/facial plastic surgery in Jonesboro

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →